A 'Polypill' aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1377/hlthaff.2011.0948

Original Paper URL
http://content.healthaffairs.org/content/32/1/155.abstract

Indexing Status
Subject indexing assigned by NLM

MeSH
Aged; Antihypertensive Agents /administration & dosage /economics; Aspirin /administration & dosage /economics; Atenolol /administration & dosage /economics; Cardiovascular Diseases /economics /prevention & control; Cohort Studies; Cost-Benefit Analysis; Developing Countries; Drug Combinations; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors /administration & dosage /economics; Latin America; Male; Markov Chains; Middle Aged; Quality-Adjusted Life Years; Ramipril /administration & dosage /economics; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin /administration & dosage /economics; Sodium Chloride Symporter Inhibitors /administration & dosage /economics

AccessionNumber
22013005658

Date bibliographic record published
22/02/2013